In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice
- PMID: 18059281
- PMCID: PMC3174471
- DOI: 10.1038/nm1683
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice
Abstract
The success of Mycobacterium tuberculosis (Mtb) as a human pathogen relies on its ability to resist eradication by the immune system. The identification of mechanisms that enable Mtb to persist is key for finding ways to limit latent tuberculosis, which affects one-third of the world's population. Here we show that conditional gene silencing can be used to determine whether an Mtb gene required for optimal growth in vitro is also important for virulence and, if so, during which phase of an infection it is required. Application of this approach to the prcBA genes, which encode the core of the mycobacterial proteasome, revealed an unpredicted requirement of the core proteasome for the persistence of Mtb during the chronic phase of infection in mice. Proteasome depletion also attenuated Mtb in interferon-gamma-deficient mice, pointing to a function of the proteasome beyond defense against the adaptive immune response. Genes that are essential for growth in vitro, in vivo or both account for approximately 20% of Mtb's genome. Conditional gene silencing could therefore facilitate the validation of up to 800 potential Mtb drug targets and improve our understanding of host-pathogen dynamics.
Conflict of interest statement
The authors declare no competing financial interest.
Figures




Similar articles
-
Simultaneous analysis of multiple Mycobacterium tuberculosis knockdown mutants in vitro and in vivo.PLoS One. 2010 Dec 22;5(12):e15667. doi: 10.1371/journal.pone.0015667. PLoS One. 2010. PMID: 21203517 Free PMC article.
-
Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity.Mol Microbiol. 2006 Mar;59(5):1405-16. doi: 10.1111/j.1365-2958.2005.05035.x. Mol Microbiol. 2006. PMID: 16468985
-
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.PLoS Pathog. 2010 Aug 12;6(8):e1001040. doi: 10.1371/journal.ppat.1001040. PLoS Pathog. 2010. PMID: 20711362 Free PMC article.
-
Deciphering the role of VapBC toxin-antitoxin systems in Mycobacterium tuberculosis stress adaptation.Future Microbiol. 2024;19(18):1587-1599. doi: 10.1080/17460913.2024.2412447. Epub 2024 Oct 21. Future Microbiol. 2024. PMID: 39431307 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
-
Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy.PLoS Pathog. 2022 Mar 28;18(3):e1010459. doi: 10.1371/journal.ppat.1010459. eCollection 2022 Mar. PLoS Pathog. 2022. PMID: 35344572 Free PMC article.
-
The mycobacterial Mpa-proteasome unfolds and degrades pupylated substrates by engaging Pup's N-terminus.EMBO J. 2010 Apr 7;29(7):1262-71. doi: 10.1038/emboj.2010.23. Epub 2010 Mar 4. EMBO J. 2010. PMID: 20203624 Free PMC article.
-
Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.J Biol Chem. 2008 Dec 5;283(49):34423-31. doi: 10.1074/jbc.M805324200. Epub 2008 Oct 1. J Biol Chem. 2008. PMID: 18829465 Free PMC article.
-
Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis.Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E1983-92. doi: 10.1073/pnas.1512094113. Epub 2016 Mar 21. Proc Natl Acad Sci U S A. 2016. PMID: 27001842 Free PMC article.
-
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target.ACS Infect Dis. 2024 May 10;10(5):1612-1623. doi: 10.1021/acsinfecdis.3c00710. Epub 2024 Apr 10. ACS Infect Dis. 2024. PMID: 38597503 Free PMC article.
References
-
- Corbett EL, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–21. - PubMed
-
- Gomez JE, McKinney JDM. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004;84:29–44. - PubMed
-
- McKinney JD, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406:735–8. - PubMed
-
- Glickman MS, Cox JS, Jacobs WR., Jr A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell. 2000;5:717–27. - PubMed
-
- Stewart GR, et al. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med. 2001;7:732–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases